RxDoctor Payments Data

Jaisingh Rajput, MD

Family Medicine · Montgomery, ALNPI 1770987943

Payments from drug & device makers

$414in general payments, 2019–2025

Across 17 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$247
  • AstraZeneca$42
  • Lilly USA, LLC$29
  • Abbott$23
  • Novo Nordisk$22
  • Boehringer Ingelheim$18
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414 in reported general payments places this provider in the 40th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$28,073
Medicare patients
79
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate79$79,052
EliquisApixaban83$72,927
JardianceEmpagliflozin63$70,160
FarxigaDapagliflozin Propanediol62$67,301
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$66,876
OzempicSemaglutide49$61,925
LinzessLinaclotide59$56,339
XareltoRivaroxaban29$30,728
EntrestoSacubitril/Valsartan12$21,763
SymbicortBudesonide/Formoterol Fumarate47$14,298
Combivent RespimatIpratropium/Albuterol Sulfate16$8,813
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide137$7,837
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$6,395
Potassium Chloride370$5,534
Albuterol Sulfate HfaAlbuterol Sulfate199$5,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$42$81,598109 claims
Boehringer IngelheimJardiance, Combivent Respimat$18$78,97379 claims
PfizerEliquis$18$72,92783 claims
GSKTrelegy Ellipta$247$66,87673 claims
Novo NordiskOzempic$22$61,92549 claims
Lilly USA, LLCHumulin 70-30$29$3,09421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →